Elliott Garlock

#digitalisation and #automation of #biopharma #manufacturing workflows, leading to #smartmanufacturing - don't miss this Bruker #webinar in a few weeks, with Anna Codina Matteo Pennestri and Sergey Shilov

9

Do not miss this webinar about how to make your scientific data #FAIRdata #sciencedata and #AIready - ZONTAL and the rest of the SciY companies can certainly help!

3

1 Comment

Some great advice in this interview — featuring Jeffry Weinhuff of Visionary Ventures — relevant to all sub-sectors of #medtech. My favorite line is “investment capital is not tuition.” 😂 But the best advice stems from the insight that good exits via IPO or M&A processes with multiple buyers competing for your company require that most medtech companies must prove their value via strong commercial metrics. And doing that takes a lot of time, expertise and money. Plan, hire and raise capital accordingly. At Vensana Capital, our investment process centers on a deep analysis of every aspect of getting a breakthrough medtech innovation to market, no matter what stage of development a company is at today. We like entrepreneurs who believe their innovation can be highly impactful to patients. We love the ones who want to leave no doubt. https://lnkd.in/eDsUqgn6

81

1 Comment

Anima Biotech, led by CEO Yochi Slonim, is transforming how we understand and treat diseases by peering into the "black box" of cellular processes. By using their groundbreaking platform to visualize cellular activities in real time, Anima is advancing drug discovery—directly within living cells. This could mean faster, more accurate insights into disease mechanisms, tackling issues like the reproducibility of experimental findings. With collaborations with industry leaders like Eli Lilly and Company, Takeda, and AbbVie, Anima Biotech is making measurable progress in advancing drug discovery for complex diseases. It’s exciting to see a company of this scale and focus influencing the landscape of biotech innovation. #Biotech #DrugDiscovery #mRNA #CellularResearch #Innovation #BiotechInnovation

2

For those of you developing novel #semiconductor innovation right now, you need to listen to this week's Lab to Market Leadership podcast. Kevin Chen, PhD is someone I've known and admired for some time. The depth of background, experience and insight he brings to his role at Lam Capital, the CVC unit of Lam Research is super impressive. I was lucky enough to grab an hour of his time to talk through... - His journey from his PhD MIT through to his roles as a start-up founder, agtech start-up CEO, corporate executive at Applied Materials, and now investor. - How the breadth of his experience helps him make better investment decisions. - What he and the Lam Capital team look for when they're evaluating new opportunities. The answer may surprise you. - The top 3 things that so many entrepreneurs do wrong when they're pitching for business. - The top qualities he would like to see more entrepreneurs embrace, and that would make them more successful. - And finally, the performance of boards - why they can feel frustrating and stuck, and his views on how to get the most out of them. Enjoy!!

9

Great insights! 🤔👏 ➡️ We prefer companies addressing large unmet needs and having clear paths to regulation. ➡️ High-potential areas - precision oncology and improving AI applications in drug development. ➡️ Companies need to prioritize pipeline positioning and leverage partnerships to attract investor interests. ➡️ Deep specialization in the underlying biology. 🧬🥼🧫 🔬 🧪 #biotech #lifescience #healthcare #therapeutics #startup #founders #precisiononcology #AIapplications #drugdevelopment #venturecapital

7

Caught Flat-Footed! Back in 2018, Jon McNeill, former COO at Lyft, shared a pivotal moment from their capital-raising roadshow. Their pitch deck was dialed in—loaded with impressive growth numbers, market share stats, and the kind of forward momentum that gets investors excited. But there was a hitch: when investors started asking about Lyft’s path to profitability, they found themselves flat-footed. The focus had been entirely on growth; they weren’t prepared to answer the hard questions about sustainability and profitability. Interestingly, Uber was facing the same scrutiny. This isn’t just a story about two ride-sharing giants; it’s a wake-up call for anyone trying to make a case. When you’re up in front of people, it’s not enough to be armed with just the positives. You need to anticipate objections and address concerns. Enter Red Teaming. Red teaming, though it has military roots, is the practice of rigorously challenging your own assumptions and strategies before stepping into any high-stakes situation. It’s about asking the tough questions yourself—or having a trusted group of friends, colleagues, or peers do it for you—before your audience does. What are the potential weaknesses in your argument? What concerns might someone raise? How would you respond if someone challenged your numbers or questioned your strategy? The idea isn’t just to find answers but to build a mindset that embraces resistance and leans into tough questions. Here’s how to start red teaming to prepare for your next big moment: 1. Create a “Red Team” Document: Write down the questions you fear the most or haven’t even considered. This should be a living document where you continually add and refine questions as you gain new insights or face new challenges. 2. Seek Outside Perspectives: Don’t do this alone. Ask your friends, colleagues, and industry peers to poke holes in your argument. The tougher the questions, the better prepared you’ll be. 3. Build the Muscle: Just like any skill, getting comfortable with challenging questions takes practice. Treat every resistance as a chance to sharpen your thinking and refine your response. The goal isn’t always to have the perfect answer but to show you’ve thought critically about potential concerns. 4. Be Present in the Moment: When you’re prepared for resistance, you’re not scrambling for answers. You can stay calm, listen to what’s being asked, and respond with confidence—even if that means admitting you don’t know something but demonstrating how you’ll find the answer. If a company like Lyft can get caught flat-footed, anyone can. The real takeaway is this: you don’t need to fear the hard questions. Instead, use them as a tool to build your resilience and readiness. Don’t just prepare for the pitch—prepare for the pushback. That’s where real confidence is built. Get ahead of the curve. Try red teaming and see how your preparation translates into powerful, poised responses when it matters most.

7

1 Comment

Looking back at the past 30 years, I remember myself doing science about 55-60 hours a week, and then helping venture capitalists and biotech start-ups about 70-80 h/week. Usually unsatisfied, sometimes exhausted, but pleased overall. This overexciting workaholism was somehow interrupted last year. I had less work and a lot of mountaineering, - climbed about 5.5 Chomolungma attitudes during the year. It feels like I have reached the stage at which it is a time to start sharing experiences and understanding of the universe. This week, I started to share by publishing an analytic report at SeekigAlpha about TG Therapeutics. This small biotech company has developed a third-to-market anti-CD20 mAb for the treatment of multiple sclerosis (MS). Along with the company, this report briefly touches upon current treatments for MS, the competitive landscape of therapeutics, and the uncertainties surrounding the development of new BTK inhibitors. https://lnkd.in/drAFx9vt

12

Eli Lilly and Company's Chief Scientific Officer, Daniel Skovronsky, explains the history and importance of patents in motivating #innovation in the biopharma industry. I am grateful for the US's legal system (including our patent laws) and business environment that have allowed our highly-impactful drug development industry to grow and flourish. So many lifesaving and life-changing medications have been developed thanks to our system! #biotech #pharma #pharmaceutical #transformation #patents https://lnkd.in/eHaSadPC

12

1 Comment

Today I want to put the spotlight on Arelys Sosa, Thomas Tingelöf and Kent Moore who are the amazing founders of DREV.🔦 The problem they are tackling is that battery gigafactories, semi-conductor factories, and battery recycling plants face big challenges collecting hazardous metal micro-particles, slowing production, and they are squandering precious materials, and endangering staff. These are all individually big problems and combined this is huge.☣️ Drev has the solution to all to this with The Vault, an innovative technology powered by patent-pending dry brush technology and a revolutionary canister design, eliminates water and chemicals from the cleaning process, improves safety, and enables the adaptive reuse of valuable materials that would otherwise be thrown away with save manufactures millons. 🧹 The Drev team has the unique domain experience for solving a particular problem that we're always looking for when we are backing founders at the Norrsken Accelerator. Arelys is an industrial engineer who was part of the original team at Panasonic Energy at Tesla’s Gigafactory 1 so she has seen this problem first hand for years. Thomas has a PhD and he has been the CTO of PowerCell and VP at Volvo Cars and has massively scaled technologies before.🤩 The interest from the industry is huge and they are currently running projects with some of the leading battery manufacturers. You can read more and contact them here: https://lnkd.in/d7V-mKrx

69

7 Comments

What if we could generate novel protein therapeutics using new computational tools, without having to discover them through trial and error? That’s what we at Flagship Pioneering asked ourselves in founding Generate:Biomedicines. With new, computationally-derived medicines now advancing in the clinic, the answer is clear: we can revolutionize drug development.

61

#hiring If anyone knows an awesome engineer that would be interested in joining an emerging #AI company doing important work in #healthcare, please drop me a line! Andy AI is backed by General Catalyst, YCombinator, Greater Ventures, and others, and they’re looking to hire a full stack engineer (US based) who's excited about using AI to improve healthcare and reduce nurse burnout. Andy is AI software that automates clinical documentation for nurses who do home visits. A nurse makes an audio recording of the visit and Andy automatically generates a form that usually takes nurses 90 minutes to complete. Nurses love the product because it potentially saves them 15 hours of charting a week! The founders previously built healthcare AI at Google Health and Apple, and are now building their vision to transform home health. More about Andy AI: https://with-andy.com/ Nurses love it: https://lnkd.in/g9XqZrUq #GenAI #digitalhealth #hiring #engineers #healthtech

26

2 Comments

After $400M of capital invested and 30 portfolio companies in health and pharma tech, we are excited to publish our SignalFire health and pharma tech sector thesis, 2024 edition and beyond! 👊 Here are 5 major trends that we're focused on 📈 If you are a founder building in any of these categories below, we'd love to hear from you! 1) Explosion of healthcare data creates both opportunities & risks in the GPT-4 era 2) PharmaTech is accelerating R&D, manufacturing & distribution to tackle inefficiencies 3) The labor shortage crisis and the need for AI to improve productivity 4) Aging population and the shift to hybrid, value-based care models in patients’ homes  5) Scaling access to lifesaving therapeutic breakthroughs: GLP-1s & CGTs Grateful to work closely with an incredible team focused on this sector including our legendary Eric Larsen, and partners in crime Sooah Cho, Tony Pezzullo, Sahir Raoof, Adele English 🙏 What gets me up every morning is our incredible portfolio, each of which making their own dent in our healthcare system for the better — Grow Therapy, Color, Ro, CodaMetrix, Health Gorilla, Verse, Wellth, PayZen, Recora, all.health, Bicycle Health, Form Health, Health Note, Osso VR, Praia Health, Freshpaint, Auxilius, Ovation, OrthoFX, Moxie and many others coming out of stealth soon 🚀 #healthtech #pharmatech #sectorthesis #innovation https://lnkd.in/gDE3nQqK

329

37 Comments

"The idea of America as the Arsenal of Democracy in World War II—innovative, productive, and hard-working—is now firmly a part of the story we tell about ourselves. It is a source of pride, patriotism, and inspiration. And it’s a true story. But that was then, and this is now. Today, Americans are waking up to the reality that we can’t make things in sufficient quantities to keep us safe, while our principal adversary is flooding the world with its manufactures. Many of our allies are in even worse shape. Rebuilding and rearming before it’s too late are the urgent tasks before us. Thankfully, industrial decline is a solvable problem—anda choice. We can make better choices, create better incentives, and use the strengths we still have to our advantage. Not only is mass production a solvable problem. It’s already being solved. Half of our business at Palantir Technologies, where I work as chief technology officer, is with commercial clients. We work every day to create software that helps the free world’s most important industrial concerns supercharge production, see into their supply chains, and empower their workers, from the C-suite to the assembly line. I’ve seen the results, and I believe this model—what’s sometimes called software-defined production—is key to rebuilding the American industrial base." https://lnkd.in/g_MPzfFH

2

Under the leadership of Ron Alfa, MD, PhD, NOETIK is pushing the boundaries of AI-driven precision cancer therapies. Noetik’s recent $40 million Series A financing will further their mission to leverage machine learning for personalized medicine, reflecting a broader industry trend where AI is revolutionizing drug discovery and patient care. As AI continues to evolve, its role in transforming healthcare becomes even more critical, setting new standards for innovation and patient outcomes. Polaris Partners Khosla Ventures Breakout Ventures Wittington Ventures Zetta Venture Partners Catalio Capital Management 11.2 Capital EPIC Ventures ApSTAT Technologies Linearis @Ventures Platform Fund Yoshua Bengio David S. Wishart Jean-François Gagné Shafique Virani, MD FRCS James Hardiman #innovation #AI #Biotechnology #AIinhealthcare

28

1 Comment

One of our values at Conceivable Life Sciences is “More Open Source Than Black Box.” We don’t hide our audacious plans, we share them with the world. This philosophy guides our approach to learning and adapting from other entrepreneurs, brands, industries, and even competitors. #IVF #IVFAutomation #automation #innovation

29

A lot of people do not realize that IQT (In-Q-Tel) is actively investing in support of the U.S. pharmaceutical supply chains and to help the U.S. build global resilience into our bioeconomy, like our recent investment in Antheia, Inc. Eugene Chiu who leads our Bio investment area highlighted that….. “While the U.S. is a leader in biomanufacturing, synthetic biology, and computational biology, there is more we must do to scale these advanced technologies to solve global problems like essential medicine shortages,”. Give the investment announcement a read below…..

117

2 Comments

Evercore ISI, Research Division Senior MD & Senior Research Analyst Glenn Schorr and I drop the beat on F.R.E.A.M. in the latest Alt Goes Mainstream Going Public show. Hear Glenn discuss F.R.E.A.M. and why fees rule everything around me in alternative asset management, just like Wu-Tang Clan said in the '90s (C.R.E.A.M. - cash rules everything around me). We cover some of the most pressing topics in alternative asset management, including: * How alternative asset managers balance fee generation with returns. * Does major growth still lie ahead for alternative asset managers? * Why “fees rule everything around me,” but so does alpha generation. * Why does distribution (almost always) win in asset management? * What’s the most valuable aspect of a publicly traded alts manager having a public currency? * What is Glenn keeping his eye on for next quarter? https://lnkd.in/e5jagG9U

11